ArticlePathology oncology research : POR2024

Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer.

Eszter Molnár et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.